A coronavirus vaccine developed by Chinese state owned pharmaceutical giant Sinopharm has 79.34 % efficacy , the drugmaker announced on Wednesday . 
A statement released online by Sinopharm subsidiary Beijing Biological Products Institute said that interim analysis of data from the Phase 3 clinical trial shows that all participants who received two doses of the vaccine produced high levels of antibodies . 
The results reached the relevant technical standards of the World Health Organization and regulations issued by the National Medical Products Administration , the statement said . 
The statement added that the company has formally submitted an application to China 's National Medical Products Administration for conditional approval . 
